Avatao Biotech has received license to market Rosetta Genomics miRview mets and miRview mets (2), microRNA-based diagnostic tests in China.

miRview mets and miRview mets(2) identify the primary tumor site in metastatic cancer and cancer of unknown primary (CUP) patients.

Avatao has also obtained rights to market and sell Rosetta’s tests in its special administrative regions Hong Kong, Taiwan and Macau, as per the agreement.

Rosetta will receive upfront payments, payments upon achievement of certain regulatory and in addition to royalties from the sales of these products it will receive potential payments which will exceed $8m.

Avatao also has rights to market one additional Rosetta Genomics’ product in China

Avatao is supported by a research institute focused on microRNA technologies – Kunshan microRNA Institute.

Avatao is in the process of building a laboratory in Kunshan microRNA Institute & Biomed Park

Rosetta Genomics president and CEO Kenneth Berlin said participation in Kunshan RNAi & Biomed Park is an important step in establishing Rosetta’s miRview tests as powerful tools in diagnosing and classifying cancers in order to optimize treatment protocols.